Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis

We herein report a 42-year-old man with advanced lung adenocarcinoma and nivolumab-associated dermatomyositis. Nivolumab, an anticancer drug that is classified as an immune checkpoint inhibitor, often induces immune-related adverse events (irAEs). However, there have so far been no reports regarding...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Fumiaki, Watanabe, Yasutaka, Iwai, Yuki, Miwa, Chihiro, Nagai, Yoshiaki, Ota, Hiromitsu, Yabe, Hiroki, Demitsu, Toshio, Hagiwara, Koichi, Koyama, Nobuyuki, Koyama, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120830/
https://www.ncbi.nlm.nih.gov/pubmed/29526968
http://dx.doi.org/10.2169/internalmedicine.9381-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120830/
https://www.ncbi.nlm.nih.gov/pubmed/29526968
http://dx.doi.org/10.2169/internalmedicine.9381-17

Ejemplares similares